TCIM
CYTK icon

TIAA CREF Investment Management’s Cytokinetics CYTK Stock Holding History

TIAA CREF Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.25M Buy
154,335
+58,003
+60% +$426K ﹤0.01% 2219
2018
Q4 		$609K Sell
96,332
-626
-0.6% -$4.59K ﹤0.01% 2485
2018
Q3 		$955K Sell
96,958
-4,288
-4% -$34.4K ﹤0.01% 2439
2018
Q2 		$840K Sell
101,246
-35,517
-26% -$296K ﹤0.01% 2562
2018
Q1 		$985K Sell
136,763
-96,111
-41% -$824K ﹤0.01% 2452
2017
Q4 		$1.9M Sell
232,874
-24,614
-10% -$279K ﹤0.01% 2167
2017
Q3 		$3.73M Sell
257,488
-1,929
-0.7% -$26.4K ﹤0.01% 1803
2017
Q2 		$3.14M Buy
259,417
+151,869
+141% +$2.11M ﹤0.01% 1895
2017
Q1 		$1.38M Buy
107,548
+9,162
+9% +$107K ﹤0.01% 2348
2016
Q4 		$1.2M Sell
98,386
-9,966
-9% -$106K ﹤0.01% 2439
2016
Q3 		$995 Sell
108,352
-580
-0.5% -$6.05K ﹤0.01% 2545
2016
Q2 		$1.03M Sell
108,932
-14,075
-11% -$115K ﹤0.01% 2491
2016
Q1 		$867K Sell
123,007
-116,538
-49% -$851K ﹤0.01% 2548
2015
Q4 		$2.51M Sell
239,545
-5,254
-2% -$51.5K ﹤0.01% 2018
2015
Q3 		$1.64M Buy
244,799
+50,674
+26% +$346K ﹤0.01% 2267
2015
Q2 		$1.3M Buy
194,125
+35,736
+23% +$234K ﹤0.01% 2558
2015
Q1 		$1.07M Hold
158,389
– – ﹤0.01% 2581
2014
Q4 		$1.27M Sell
158,389
-24,270
-13% -$104K ﹤0.01% 2522
2014
Q3 		$643K Sell
182,659
-180,211
-50% -$757K ﹤0.01% 2870
2014
Q2 		$1.74M Buy
362,870
+81,235
+29% +$496K ﹤0.01% 2385
2014
Q1 		$2.68M Buy
281,635
+61,533
+28% +$557K ﹤0.01% 2056
2013
Q4 		$1.43M Buy
220,102
+88,400
+67% +$581K ﹤0.01% 2452
2013
Q3 		$1M Buy
131,702
+6,152
+5% +$66K ﹤0.01% 2600
2013
Q2 		$1.45M Buy
+125,550
New +$989K ﹤0.01% 2350

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

TIAA CREF Investment Management's CYTK Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Cytokinetics (CYTK) stake by 60% in Q1 2019, buying an estimated $426K and bringing the position to 154,335 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2219.

TIAA CREF Investment Management first reported a position in CYTK in Q2 2013 and has held it in 24 quarters since. The position peaked at $3.73M in Q3 2017. 138 funds tracked by Wall St. Rank hold CYTK as of Q1 2019.

  • TIAA CREF Investment Management held 154,335 shares of Cytokinetics worth $1.25M as of Q1 2019.
  • TIAA CREF Investment Management bought 58,003 Cytokinetics shares in Q1 2019, an estimated $426K.
  • Cytokinetics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2219 holding.
  • TIAA CREF Investment Management first reported a position in Cytokinetics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Cytokinetics position peaked at $3.73M in Q3 2017.
  • 138 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.